当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Is cigarette smoking a risk factor for non-Hodgkin's lymphoma or multiple myeloma? Results from the Lutheran Brotherhood Cohort Study.

Is cigarette smoking a risk factor for non-Hodgkin's lymphoma or multiple myeloma? Results from the Lutheran Brotherhood Cohort Study.

Abstract：

:Among 17,633 U.S. white male insurance policy holders whose use of tobacco was characterized in a 1966 self-administered questionnaire, there were 49 deaths from non-Hodgkin's lymphoma (NHL) and 21 from multiple myeloma (MM) during a 20-year follow-up. Men who had ever smoked cigarettes had an elevated mortality from NHL (RR = 2.1; CI = 0.9-4.9), with risk almost four-fold greater among the heaviest smokers (RR = 3.8; CI = 1.4-10.1) compared with those who used no tobacco. In contrast, risk of MM was only slightly elevated among those who had ever smoked cigarettes (RR = 1.3; CI = 0.4-3.9) and without evidence of a dose-response trend. Since this is the first cohort study suggesting a link between cigarette smoking and NHL and findings from case-control studies have been inconsistent, additional clarification should be sought from larger incidence-based cohort investigations.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Linet MS,McLaughlin JK,Hsing AW,Wacholder S,Co Chien HT,Schuman LM,Bjelke E,Blot WJ

doi

10.1016/0145-2126(92)90011-u

keywords:

subject

Has Abstract

pub_date

1992-06-01 00:00:00

pages

621-4

issue

6-7

eissn

0145-2126

issn

1873-5835

pii

0145-2126(92)90011-U

journal_volume

16

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Telomerase gene screening and telomere overhang detection in Chinese patients with myelodysplastic syndrome.

    abstract：BACKGROUND:Telomerase disfunction leads to short telometric overhangs, potentially resulting in chromosome instability. AIMS:To better understand the role of overhang length in the progression of myelodysplastic syndrome (MDS). METHODS:Bone marrow samples of 62 Chinese MDS patients were screened for TERT and TERC gen...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2013.06.011

    authors： Yan S,Han B,Li H,Wu Y,Zhou D,Zhao Y

    更新日期：2013-10-01 00:00:00

  • Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation.

    abstract：:The involvement of histone lysine methyltransferases (HMT) in carcinogenesis is not well understood. Here, we describe a dose-dependent growth and survival inhibitory effects of BIX-01294, a specific inhibitor of euchromatic HMT2, in promyelocytic leukemia HL-60 and NB4 cells. BIX-01294 combined with all-trans retinoi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2014.04.003

    authors： Savickiene J,Treigyte G,Stirblyte I,Valiuliene G,Navakauskiene R

    更新日期：2014-07-01 00:00:00

  • Effect of prostaglandin E2 on gamma-interferon and 1,25(OH)2D3 vitamin D3-induced c-myc reduction during HL-60 cell differentiation.

    abstract：:The effect of prostaglandin E2 (PGE2) on the reduction of c-myc expression during the differentiation of the human leukemic cell line, HL-60, was examined. PGE2, a potent inducer of intracellular cyclic AMP (cAMP) in HL-60 cells, augmented monocyte-associated cell surface antigens induced by human gamma-interferon (IF...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(88)90090-2

    authors： Matsui T,Nakao Y,Koizumi T,Katakami Y,Takahashi R,Mihara K,Sugiyama T,Fujita T

    更新日期：1988-01-01 00:00:00

  • Combined effects of interferon and steroid hormones on 2',5'-oligoadenylate synthetase activity in chronic lymphocytic leukemia cells.

    abstract：:2',5'-oligoadenylate synthetase (OAS) has been implicated in the effects of interferons (INF) and steroid hormones on cell growth and differentiation. We studied the combined effects in vitro of hormones and INF on OAS activity in cells from 10 patients with chronic lymphocytic leukemia. IFN enhanced OAS activity in a...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(89)90163-x

    authors： Triozzi PL,Avery KB,Abou-Issa HM,Chou TC

    更新日期：1989-01-01 00:00:00

  • Erythropoietin.

    abstract：:The remarkable capacity of the bone marrow to compensate for blood loss and for reduced atmospheric oxygen tension has been found to be mediated by a renal hormone, named erythropoietin. It is produced by peritubular interstitial cells in response to renal hypoxia, but molecular engineering has permitted large scale p...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/0145-2126(90)90094-p

    authors： Erslev AJ

    更新日期：1990-01-01 00:00:00

  • What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL?

    abstract：:We report the case of an elderly patient affected by Philadelphia positive Acute Lymphoblastic Leukaemia (Ph(+) ALL) who developed meningeal leukaemia during imatinib monotherapy, despite bone marrow molecular remission. Aggressive central nervous system (CNS)-directed therapy in combination with continued imatinib tr...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.03.018

    authors： Mele G,Pinna S,Melpignano A,Romano A,Brocca MC,Coppi MR,Quarta G

    更新日期：2007-10-01 00:00:00

  • Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.

    abstract：:To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher ...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2011.05.015

    authors： Latagliata R,Breccia M,Castagnetti F,Stagno F,Luciano L,Gozzini A,Ulisciani S,Cavazzini F,Annunziata M,Sorà F,Rossi AR,Pregno P,Montefusco E,Abruzzese E,Crisà E,Musto P,Tiribelli M,Binotto G,Occhini U,Feo C,Vigner

    更新日期：2011-09-01 00:00:00

  • A novel Ph1 chromosome positive cell line established from a patient with chronic myelogenous leukemia in blastic crisis.

    abstract：:A novel Philadelphia (Ph1) chromosome positive cell line, designated KYO-1, was established from the peripheral blood of a patient with chronic myelogenous leukemia (CML) in blastic crisis. Although this line had a unique capacity to differentiate spontaneously along the erythroid and monocytoid lineages as evidenced ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(85)90314-5

    authors： Ohkubo T,Kamamoto T,Kita K,Hiraoka A,Yoshida Y,Uchino H

    更新日期：1985-01-01 00:00:00

  • Acute myeloid leukemia with hypergranular cytoplasm accompanied by t(X;11)(q24;q23) and rearrangement of the MLL gene.

    abstract：:This report describes a unique case of acute myeloid leukemia with hypergranular cytoplasm and t(X;11)(q24;q23). The breakpoint on 11q23 was identified within the MLL gene. The hypergranular cytoplasm of leukemic cells and the associated coagulopathy resembled a characteristic of acute promyelocytic leukemia, despite ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)00131-3

    authors： Nakata Y,Mori T,Yamazaki T,Suzuki T,Okazaki T,Kurosawa Y,Kinoshita A,Ohyashiki K,Nakazawa S

    更新日期：1999-01-01 00:00:00

  • Physical and functional interactions between hematopoietic cell-specific ETS transcription factors and homeodomain proteins.

    abstract：:To examine the possibility that ETS family transcription factors, PU.1, SPI-B, ELF-1, ERG-3, ETS-1 and TEL, and homeodomain proteins, HOXA10, HOXC13, MEIS1 and PBX1B, function cooperatively, we investigated their interactions. In luciferase assays, HOXA10 and HOXC13 augmented the activity of PU.1 and SPI-B while dimin...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.07.002

    authors： Yamada T,Shimizu T,Sakurai T,Nanashima N,Kihara-Negishi F,Suzuki M,Fan Y,Akita M,Oikawa T,Tsuchida S

    更新日期：2009-03-01 00:00:00

  • Myelodysplastic syndrome associated with Griscelli syndrome.

    abstract：:Myelodysplastic syndrome (MDS) in children has been reported to be associated with various constitutional anomalies; however, it has not been described previously in patients with Griscelli syndrome (GS). In this report, we present a case with GS and refractory anemia with an excess of blasts. We believe that careful ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)00075-7

    authors： Cetin M,Hiçsönmez G,Göğüş S

    更新日期：1998-09-01 00:00:00

  • Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.

    abstract：:Although recent advances in chemotherapy have markedly improved outcome of acute lymphoblastic leukemia (ALL), infantile ALL with MLL gene rearrangements (MLL+ALL) is refractory to chemotherapy. We have shown that specific cytokines FLT3 ligand and TGFβ1 both of which are produced from bone marrow stromal cells synerg...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2018.11.001

    authors： Ando N,Furuichi Y,Kasai S,Tamai M,Harama D,Kagami K,Abe M,Goi K,Inukai T,Sugita K

    更新日期：2018-12-01 00:00:00

  • Enhancement of J6-1 human leukemic cell proliferation by membrane-bound M-CSF through a cell-cell contact mechanism II. Role of an M-CSF receptor-like membrane protein.

    abstract：:We have isolated an M-CSF-like membrane-associated growth factor from human leukemic J6-1 cells that can enhance the growth and colony formation of J6-1 cells in vitro. Indirect evidence suggests that this membrane-associated M-CSF-like growth factor may do so by stimulating a corresponding receptor co-expressed on th...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(97)00135-5

    authors： Wu KF,Rao Q,Zheng GG,He ZH,Ying HG,Song YH,Chen BD

    更新日期：1998-01-01 00:00:00

  • Establishment and characterization of a B-cell line from a patient with acute lymphoblastic leukemia.

    abstract：:A permanent lymphoblastoid cell line was established from the peripheral blood of a child with acute lymphoblastic leukemia. The cell line, designated SDK, grows in a stationary suspension culture, forming aggregates, in RPMI medium supplemented with 10% FCS, with a doubling time of 50-60 h. Immunologic markers and cy...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(85)90025-6

    authors： Kottaridis S,Perez S,Kokkinopoulos D,Delinassios JG,Pangalis GA,Cosmidis H,Goula I,Papamichail M

    更新日期：1985-01-01 00:00:00

  • Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution.

    abstract：:The aim of this study was to describe the presenting features, the frequency and outcome of myeloid sarcoma (MS) diagnosed in our Institution from January 1995 to December 2000. Twelve MS were seen and the frequency account for only 2% of all acute myeloid leukemia (AML) patients observed in our department in the same...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2004.01.022

    authors： Breccia M,Mandelli F,Petti MC,D'Andrea M,Pescarmona E,Pileri SA,Carmosino I,Russo E,De Fabritiis P,Alimena G

    更新日期：2004-11-01 00:00:00

  • Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).

    abstract：:We investigated the role of Src family kinases (SFKs) in the regulation of STAT activation in myeloid leukemia cells. Two of 6 AML cell lines displayed constitutive STAT5 activation, whereas four cell lines had constitutive SFK activity. Treatment with the SFK inhibitors suppressed STAT5 activation and decreased viabi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.11.032

    authors： Ozawa Y,Williams AH,Estes ML,Matsushita N,Boschelli F,Jove R,List AF

    更新日期：2008-06-01 00:00:00

  • Comparison of 18F FDG PET-CT AND CECT in pretreatment staging of adults with Hodgkin's lymphoma.

    abstract：:We compared 2-[fluorine-18] fluoro-2-deoxy-d-glucose PET-CT and contrast-enhanced computed tomography (CECT) in 62 consecutive patients with newly diagnosed Hodgkin Lymphoma (HL), aiming to provide evidences that may spare CECT from the staging procedures of HL patients. Among a total of 1448 nodal sites examined, dis...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2018.11.018

    authors： Panebianco M,Bagni O,Cenfra N,Mecarocci S,Ortu La Barbera E,Filippi L,Codacci-Pisanelli G,Biondi T,Laghi A,Cimino G

    更新日期：2019-01-01 00:00:00

  • Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.

    abstract：:Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied. In a total of 49 patients, the MEP regime...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0145-2126(01)00114-x

    authors： Murohashi I,Kashimura T,Tominaga K,Wakao D,Takahashi T,Akiba M,Kishimoto K,Yoshida K,Yagasaki F,Itoh Y,Sakata T,Kawai N,Itoh K,Suzuki T,Matsuda A,Hirashima K,Bessho M

    更新日期：2002-03-01 00:00:00

  • Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.

    abstract：:Aggressive systemic mastocytosis (ASM) is a hematopoietic neoplasm characterized by infiltration of visceral organs by neoplastic mast cells (MCs) with consecutive organopathy and respective clinical and laboratory findings (so called C-Findings). Whereas, it is generally appreciated that patients with ASM are candida...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/s0145-2126(03)00259-5

    authors： Hauswirth AW,Simonitsch-Klupp I,Uffmann M,Koller E,Sperr WR,Lechner K,Valent P

    更新日期：2004-03-01 00:00:00

  • Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.

    abstract：:ABCG2 encodes a transporter protein that is associated with multidrug-resistant phenotypes in many cancers, including acute myeloid leukemia (AML); high levels of expression are generally associated with a poor prognosis. To better understand how expression of ABCG2 is controlled in pediatric AML, we performed a detai...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2011.05.004

    authors： Campbell PK,Zong Y,Yang S,Zhou S,Rubnitz JE,Sorrentino BP

    更新日期：2011-10-01 00:00:00

  • Immunohistochemical classification of acute leukemias using peripheral blood smears.

    abstract：:Immunophenotypic classification of the acute leukemias (AcL) is of well documented value in those of lymphoid or uncertain origin and of increasing importance in those of nonlymphoid origin. Most of these studies have been performed on viable cell suspensions. To study the efficacy of a simpler immunohistochemical app...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90080-4

    authors： Vago JF,Hurtubise PE,Martelo OJ,Swerdlow SH

    更新日期：1987-01-01 00:00:00

  • A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.

    abstract：:Oblimersen selectively targets Bcl-2 mRNA and has been shown to enhance the apoptotic activity of various antileukemic agents, including gemtuzumab ozogamicin (GO), in preclinical studies. We evaluated the efficacy and safety of oblimersen combined with GO in patients > or =60 years of age in first relapse with CD33+ ...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2005.10.025

    authors： Moore J,Seiter K,Kolitz J,Stock W,Giles F,Kalaycio M,Zenk D,Marcucci G

    更新日期：2006-07-01 00:00:00

  • Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

    abstract：:Hypereosinophilic syndrome (HES) is characterized by sustained non-clonal blood and tissue eosinophilia, leading to end-organ damage. With a molecular/cytogenetic clonality marker, the disease is classified as chronic eosinophilic leukemia (CEL). Efficacy of imatinib mesylate is well established in CEL with FIP1L1-pla...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.10.004

    authors： Jain N,Cortes J,Quintás-Cardama A,Manshouri T,Luthra R,Garcia-Manero G,Kantarjian H,Verstovsek S

    更新日期：2009-06-01 00:00:00

  • Sustained disease control in transplant-ineligible patients: the role of continuous therapy.

    abstract：:Many patients with multiple myeloma (MM) are elderly (aged >65 years) or unfit, and therefore ineligible for stem-cell transplantation. The novel agents thalidomide, bortezomib, and lenalidomide have shown improved outcomes in these patients. This article discusses the role of continuous therapy in improving patient o...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/S0145-2126(12)70005-X

    authors： Palumbo A,Niesvizky R

    更新日期：2012-11-01 00:00:00

  • Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.

    abstract：:Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for mobilization may aggravate bortezomib-induced polyneuropathy. In t...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.03.015

    authors： Keller S,Seipel K,Novak U,Mueller BU,Taleghani BM,Leibundgut K,Pabst T

    更新日期：2015-07-01 00:00:00

  • Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL.

    abstract：:Leukemic cell lines have become important tools for studies of disease providing a monoclonal cell population that can be extensively expanded in vitro while preserving leukemic cellular characteristics. However, studies of chronic lymphocytic leukemia (CLL) have been impeded in part by the lack of continuous human ce...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.10.008

    authors： Kellner J,Wierda W,Shpall E,Keating M,McNiece I

    更新日期：2016-01-01 00:00:00

  • The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.

    abstract：:Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated wi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.02.002

    authors： Salar A,Haioun C,Rossi FG,Duehrsen U,Pettengell R,Johnsen HE,Jaeger U,Verhoef G,Schwenkglenks M,Bacon P,Bendall K,Lugtenburg PJ

    更新日期：2012-05-01 00:00:00

  • Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

    abstract：:Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/s0145-2126(96)00116-6

    authors： Ruutu T,Hänninen A,Järventie G,Koistinen P,Koivunen E,Kätkä K,Nousiainen T,Oksanen K,Pelliniemi TT,Remes K,Timonen T,Volin L,Elonen E

    更新日期：1997-02-01 00:00:00

  • Molecular characterization and prognostic significance of FLT3 in CML progression.

    abstract：:To characterize the molecular mechanisms involved in the transition from the chronic phase to blast crisis in chronic myelogenous leukemia (CML), gene expression profiles of leukemic cells from patients in the chronic and blast crisis phases were analyzed using an 8.7K cDNA chip and real-time PCR. A transient transfec...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.11.008

    authors： Kim KI,Park J,Ahn KS,Won NH,Kim BK,Shin WG,Yoon SS,Oh JM

    更新日期：2010-08-01 00:00:00

  • Ionic currents in multidrug resistant K562 human leukemic cells.

    abstract：:In this study, the expression and functional characterization of currents through the CFTR (cystic fibrosis transmembrane regulator) and ORCC (outwardly rectifying chloride channels) were determined in wild-type K562 chronic human leukemia cells (K562-WT) and in its resistant counterpart, the vincristine resistant cel...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.02.007

    authors： Assef YA,Cavarra SM,Damiano AE,Ibarra C,Kotsias BA

    更新日期：2005-09-01 00:00:00